Orange Biomed ’s Post

🌟 RapidFor HbA1c Rapid Test Kit (FIA): A Leap Forward in Diabetes Management 🌟 🔍 Precision & Speed: The RapidFor HbA1c Rapid Test Kit delivers fast, accurate results for glycated hemoglobin levels, crucial for managing diabetes effectively. Its technology ensures timely insights, enabling prompt adjustments to care plans. 🏅 Certified Quality: Boasting NGSP and IFCC certifications, the kit meets stringent global standards for accuracy, offering confidence in every result. 🔬 Versatile Application: Designed for both point-of-care and laboratory use, it accommodates capillary and venous samples, making it a flexible option for various clinical settings. 👩⚕️ Enhanced Patient Care: This kit enables personalized treatment and greater patient involvement in their diabetes management, thanks to its quick and reliable measurements. 🔄 Streamlined Workflow: By minimizing administrative tasks, it allows healthcare providers to focus more on patient care, improving efficiency and satisfaction. Integrating the RapidFor HbA1c Rapid Test Kit into your practice not only optimizes diabetes management but also aligns with the goal of delivering patient-centered, efficient healthcare. #Diabetes #HbA1c #HbA1cTesting #RapidTestKits #PointofCareTesting #RapidForHbA1cRapidTestKit #FIAPro #Vitrosens #VitrosensBiotechnology #InTestWeTrust Visit our website to read our latest blog and follow the latest news in the world of biotechnology. https://lnkd.in/dS93JQ5u

Despite incredible healthcare advancements, diabetes management still faces significant hurdles. Accessing data, integrating remote monitoring, and managing time and resources can be overwhelming. That’s where SweetSpot steps in. Our platform & service is a game-changer for diabetes care: ✅ Unified Data: We bring together CGM and insulin delivery data onto a single dashboard for effortless patient information management. ✅ Smart Coding: Our algorithm optimizes CPT coding, ensuring maximum revenue without compromising care quality. ✅ End-to-End Support: From patient consent & device troubleshooting to expert CDCES reviews, we’re here to make your transition to SweetSpot seamless. Clinics managing 200-300 CGM patients are already seeing net income over $250,000 annually with SweetSpot. Ready to step into the future of diabetes device management? 👉 Explore our website, connect on LinkedIn for updates, and request a demo and chat with the founders! 🌍 https://lnkd.in/e83frghU #DiabetesCare #CDCES #Endocrinology #Diabetes #CGM #Insulin #RPM

The landscape of diabetes management is rapidly evolving, with groundbreaking innovations like Continuous Glucose Monitors (CGMs) and Smart Insulin Pens making care more efficient and patient-friendly. CGMs provide continuous, real-time monitoring of blood glucose levels, eliminating the need for constant finger pricking. They offer valuable insights, allowing both patients and doctors to track glucose fluctuations and make informed adjustments to treatment plans. Smart Insulin Pens are another game-changer, recording insulin doses and timing, helping patients avoid missed or incorrect doses. These devices provide reminders and sync with apps, ensuring precise insulin management and reducing the risk of complications. Together, these innovations improve patient outcomes, enhance convenience, and empower individuals to manage their diabetes with confidence. At Dr. Palve Hospital, we are committed to integrating the latest technologies into our diabetic care services, ensuring our patients receive personalized and cutting-edge treatments. #DiabetesCare #HealthTech #InnovativeHealthcare #ContinuousGlucoseMonitoring #SmartInsulinPen #DrPalveHospital #PatientFirst #DiabetesManagement

🌍 𝐖𝐨𝐫𝐥𝐝 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐃𝐚𝐲: Medical Devices for Safer, More Effective Diabetes 📅 Today, on #worlddiabetesday , we recognize the global impact of diabetes – a condition that affects over 537 million people worldwide. This means one in 10 adults has diabetes! With numbers projected to rise and the latest medical devices, managing diabetes is more efficient and personalized than ever. ➡️ Read our article (https://tiny.pl/f8yfwnnd) to learn about the innovative devices enhancing diabetic care: 🔹 Continuous Glucose Monitors (CGM) – small sensors placed under the skin provide real-time glucose data, alerting users when levels are too high or low. 🔹 Smart Insulin Pens – advanced pens helping to calculate the correct dose of insulin 🔹 Blood Glucose Meters and Insulin Pumps – Reliable standards for daily care 🔹 Combined CGM and Insulin Pumps – the integration allowing continuous glucose monitoring paired with automated insulin delivery, pushing diabetes care into the future. Innovations in diabetes care bring valuable improvements, but each device undergoes rigorous scrutiny before reaching patients. In the EU, the Medical Device Regulation (MDR) ensures devices meet stringent safety standards, varying by device class (I to III) based on risk and function. The more complex the device, the more rigorous the premarket investigations. Devices are also monitored post-market, with manufacturers providing regular reports to maintain high safety standards. Inspired to develop an innovating hasztag#medicaldevice to make #diabetes life easier but afraid of regulations? Let us to help you. Our experts at SciencePharma are here to guide you through the compliance and notification procedures required by Regulations (EU) 2017/745 and 2017/746. Even if there are still some devices covered by the transitional period, even till 2029, do not hesitate and adapt your medical devices to new requirements immediately. ✨ We’re here to support the future of diabetes care. ✨ #DiabetesCare #MedicalTechnology #HealthTech #MDR #EURegulations #ContinuousGlucoseMonitor #InsulinPens #SmartDevices #DiabetesAwareness #PatientSafety

Endocrinologists and diabetes educators often juggle multiple management platforms—Glooko, Tidepool, Dexcom Clarity, Tandem Source, Medtronic CareLink, and more to support their patients with diabetes. With endo.digital, we’re changing the game. By harnessing CGM data, endo.digital streamlines insulin management with smart recommendations for bolus dosing (including carb counting) and basal adjustments throughout the day, all integrated into your current EMR. The result? Providers gain an extra eight minutes per appointment to focus on what truly matters: building a deeper connection with their patients. #diabetes #cgm #diabetestech #healthcare #endocrinologists

What are the most common myths about respiratory drug delivery that you hear? The science behind respiratory drug delivery is complex, and consequently there are lots of myths floating around. We wanted to tackle some of the most common myths head on, so we will be publishing a series of blog posts, each addressing a common myth about DPIs that we often hear. For example, in the first blog of the series, we debug the common myth that lower resistance DPIs are “easier to use”. What are some of the common myths you often hear? Comment below! https://lnkd.in/dd8rbWar #DPIs #respiratorymedicine #respiratorydrugdelivery #inhalers

📢Dexcom introduces new diabetes management technology Dexcom ONE+ Dexcom ONE+ is designed to leverage the company’s most accurate sensor design and is developed using feedback from both end users and healthcare professionals. The new CGM system is currently available in Spain, Belgium, and Poland, with plans to launch in the Netherlands next week, and additional countries in the coming months. Dexcom ONE+ would replace the previous generation Dexcom ONE sensor in some countries, said the company. Dexcom executive vice president and chief commercial officer Teri Lawver said: “Dexcom ONE+ incorporates our best-in-class technology and a range of features that we know will be well-received by the diabetes community. “By building Dexcom ONE+ based on user and healthcare professional feedback we know we have a CGM system that is flexible, easy to get started with, and intuitive to use; a system that people with either Type 1 or Type 2 diabetes, and their care teams, can benefit from.” According to Dexcom, people who manage diabetes using finger pricks and regularly inject insulin may feel suppressed by the disease. The Dexcom ONE+, which is easy to get started with and easy to live with, even for those with no experience of using a CGM system, is designed to reduce the disease burden. Read more online: https://lnkd.in/e2KBKAdx 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #dexcom #diabetesmanagement

The recent FDA clearance of the Eversense 365 CGM system marks a transformative moment in diabetes care, promising to significantly alleviate the daily challenges faced by individuals managing the condition. By enabling a full year of continuous glucose monitoring with minimal disruption, this advanced device not only enhances patient compliance and lifestyle flexibility but also opens avenues for better integration with emerging automated insulin delivery systems. As the industry continues to innovate, Eversense 365 exemplifies how long-term solutions can fundamentally change patient experiences, reducing reliance on frequent device management and fostering greater independence in diabetes management. The anticipated launch and potential collaborations with pump manufacturers signal a bright future for comprehensive diabetes care. For additional information, click here: https://rb.gy/68zfc5. #Senseonics #Eversense365 #ContinuousGlucoseMonitoring #DiabetesCare #FDAApproval #DiabetesTechnology #Type1Diabetes #Type2Diabetes #CGMInnovation #LongTermCGM #HealthTech #PatientCare #InsulinDelivery #DiabetesManagement #LivingWithDiabetes #HealthcareRevolution #GlucoseMonitoring #DiabetesAwareness #AscensiaDiabetesCare #MedicalTechnology #A1cControl #DiabetesFreedom #CGMSystem #DiabetesSupport

What if you could get your blood tested for common conditions without having to make multiple trips to the doctor or the lab? What if you could have your blood taken with a device that fits right over your fingertip? What if you could have your blood tested in a place that is convenient and accessible, such as your local pharmacy or clinic? That's the vision of the BD MiniDraw™ Capillary Blood Collection System, a groundbreaking device that enables lab-quality results from blood obtained through a simple fingerstick. The BD MiniDraw™ requires only six to 18 drops of blood, compared to 100, 150, or 200 drops for venous blood tests. Blood collected can be used to perform tests such as lipid panel, selected chemistry tests, and hemoglobin and hematocrit, which are used to diagnose and monitor chronic conditions such as hypertension and high cholesterol. The BD MiniDraw™ is intended for use by health care professionals in non-traditional care settings, such as retail pharmacies or clinics, to help make blood testing more convenient and accessible for patients, especially those who face challenges in getting to a doctor's office or a lab. Discover how the BD MiniDraw™ is making blood collection easier than ever. #BDemployee

Just released in the Blue journal/ AJRCCM-Turning the Air Blue section FDA Strategy to Evaluate Pulse Oximeters: The Same Cause Will Produce the Same Effects https://lnkd.in/dDuMjFjK This is a hot topic as the FDA currently reevaluate the general guidance for pulse oximeters evaluation. The old method developed by Severinghaus 40 years ago was suitable to evaluate initial pulse oximeters with suboptimal calibrations (1), and is still adapted for low costs pulse oximeters (2). In these cases, large bias can be detected. However, this method is not sensitive enough in other situations and the bias (SpO2-SaO2) and precision (SD of the bias) are not well evaluated in laboratory conditions with healthy subjects and are minimized (usually below 1%) in comparison with studies conducted in PATIENTS (frequently above 2%). The impact of skin pigmentation has not been detected in healthy subjects studies within usual oxygenation ranges, and was only detected during severe hypoxemia (3,4). These overly optimistic assessments are useful neither for clinicians, nor probably for pulse oximeter manufacturers who want to provide the right information on their products. It was shown in recent studies, that 2 to 4% bias or differences between pulse oximeters had a major impact on oxygen flow used and other clinical outcomes (5,6). If the FDA continues with the same method, the impact of skin pigmentation and the impact of calibration will still be minimized as it is was the case at least in the last 20 years. It is time to move forward with evaluations conducted in hospitalized patients providing the real bias and precision that the caregivers find in patients in their daily practice. This will help clinicians to manage patients requiring respiratory supports. References: 1- https://lnkd.in/dEX_-mNP 2- https://lnkd.in/gxPeDVtv 3- https://lnkd.in/dY_mwTAW 4- https://lnkd.in/dH6jrWiD 5- https://lnkd.in/de6qGkn 6- https://lnkd.in/gPG-rJ26 #pulseoximeter #SpO2 #patientsafey #FDA #pulseoxevaluation #skinpigmentation